The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
14h
Zacks.com on MSNVertex Pharmaceuticals (VRTX) Misses Q4 Earnings EstimatesVertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago.
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
The Associated Press on MSN11d
FDA approves new painkiller that shows promise and challenges of opioid alternativesThe U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
This has outpaced the Medical sector's gain of 8.26% and the S&P 500's gain of 2.71% in that time. Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a ...
trauma or painful medical procedures and is likely to ease with time. Vertex is now the first drugmaker in decades to gain U.S. approval for a new type of pain medicine. It's a milestone after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results